

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020819

CHEMISTRY REVIEW(S)

DEC 19 1997

1

DIVISION OF Metabolism and Endocrine DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA#: 20-819 CHEM. REVIEW #: 1 REVIEW DATE: 12-16-97

<u>SUBMISSION TYPE</u>	<u>DOCUMENT DATE</u>	<u>CDER DATE</u>	<u>ASSIGNED DATE</u>
NDA (Original)	1-17-97	1-23-97	1-30-97
Amendment	5-30-97	6-2-97	6-9-97
Amendment	8-1-97	8-4-97	8-6-97
Amendment	8-15-97	8-18-97	8-20-97
Amendment	8-29-97	9-2-97	9-4-97
Amendment	9-3-97	9-8-97	9-11-97
Amendment	10-1-97	10-6-97	10-8-97
Amendment	10-31-97	11-3-97	11-5-97

NAME & ADDRESS OF APPLICANT:

Abbott Laboratories
200 Abbott Park Road, D-389 AP30
Abbott Park, IL 60064-3537

DRUG PRODUCT NAME:

Proprietary: CaPTHrol™
Nonproprietary: Paricalcitol Injection
Formerly called: Paracalcin Injection

Code Name/#: None
Chem. type/Ther. Class: 1 S

PHARMACOL. CATEGORY/INDICATION:

Prevention and treatment of renal osteodystrophy and secondary hyperparathyroidism encountered with chronic renal failure.

DOSAGE FORM: Injectable solution in ampuls or vials
(given as a bolus dose)

STRENGTHS: 5 mcg/ml (total volumes: 1 ml, 2 ml, and 5 ml in ampules or vials)

ROUTE OF ADMINISTRATION: I.V.


DISPENSED: Rx OTC

CHEMICAL NAMES, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT.:

19-Nor-1-alpha,25-dihydroxy vitamin D₂
[19-nor-1 alpha,3 beta,25-trihydroxy-9,10-secoergosta-5(Z),7(E), 22(E)triene]

USAN name: Paricalcitol

C₂₇H₄₄O₃ Molecular weight: 416.65



APPROVED BY
ON BEHALF

APPROVED BY
ON BEHALF

RELATED DOCUMENTS: None
CONSULTS: Microbiology (HFD-160)

REMARKS/COMMENTS:

The amendment, dated 5-30-97 provides a discussion of some of the methodology for monitoring the Drug Product specifications. The amendment of 8-1-97 supplies: Information relative to the sterility of paracalcin in ampules, changes in the original specifications for the drug product in ampules, changes in the stability protocol for the drug product in ampules, and information to support the additions of 1 ml, 2 ml, and 5 ml glass vials including revised labeling.

CONCLUSIONS & RECOMMENDATIONS:

From a chemistry point of view, this submission is approvable pending satisfactory responses to the chemistry deficiencies in the NDA and in the _____ for the drug substance as well as an acceptable CGMP inspection. Issue an information request letter

CC:
Orig. NDA 20-819
HFD-510/Division File
HFD-510/Sheldon Markofsky
HFD-510/R. Hedin (CSO)
HFD-510/D-G. Wu (Team Leader)
HFD-580/J. Gibbs
Chemist

APPROVED
ON BEHALF

/S/

Sheldon Markofsky, Review

12-16-97

R/D Init by: Team Leader

filename: n20819e

/S/ 12/19/97

DIVISION OF Metabolism and Endocrine DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

<u>NDA#:</u> 20-819	<u>CHEM. REVIEW #:</u> 2	<u>REVIEW DATE:</u>	3-24-98
<u>SUBMISSION TYPE</u>	<u>DOCUMENT DATE</u>	<u>CDER DATE</u>	<u>ASSIGNED DATE</u>
Amendment	1-23-98	1-26-98	1-30-98
Amendment	3-3-98	3-9-98	3-10-98
Amendment (stability)	3-3-98	3-9-98	3-9-98
Amendment	3-23-98		3-24-98

NAME & ADDRESS OF APPLICANT:

Abbott Laboratories
200 Abbott Park Road, D-389 AP30
Abbott Park, IL 60064-3537

DRUG PRODUCT NAME:

Proprietary: CapThrol™
Nonproprietary: Paricalcitol Injection

APPEARS TO BE
ON ORIGINAL

Code Name/#: None
Chem. type/Ther. Class: 1 S

PHARMACOL. CATEGORY/INDICATION:

Prevention and treatment of renal osteodystrophy and secondary hyperparathyroidism encountered with chronic renal failure.

DOSAGE FORM: Injectable solution in ampuls or vials
(given as a bolus dose)

STRENGTHS: 5 mcg/ml (total volumes: 1 ml, 2 ml, and 5 ml in ampules or vials)

ROUTE OF ADMINISTRATION: I.V.

APPEARS TO BE
ON ORIGINAL

DISPENSED: X Rx OTC

CHEMICAL NAMES, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT:

19-Nor-1-alpha,25-dihydroxy vitamin D₂
[19-nor-1 alpha,3 beta,25-trihydroxy-9,10-secoergosta-5(Z),7(E), 22(E)-triene]

USAN name: Paricalcitol
C₂₇H₄₄O₃ Molecular weight: 416.65

APPEARS TO BE
ON ORIGINAL

Structure: See Chemistry Review # 1

RELATED DOCUMENTS : None
CONSULTS: Microbiology (HFD-160)

Redacted 1

pages of trade

secret and/or

confidential

commercial

information

* Samples (in vials) will be stored both inverted and upright.
Stability testing will be conducted on the first three marketed lots
in both upright and inverted storage positions.

CONCLUSIONS & RECOMMENDATIONS:

Satisfactory CMC information has been provided, and the application is
approvable from a Chemistry point of view.

cc:
Orig. NDA 20-819
HFD-510/Division File
HFD-510/Sheldon Markofsky
HFD-510/R. Hedin (CSO)
HFD-510/D-G. Wu (Team Leader)
HFD-580/J. Gibbs

APPROVED BY
ON BEHALF

/S/

Sheldon Markofsky, Review Chemist

3-24-98

R/D Init by: Team Leader

filename: n20819.2a

/S/

3/24/98

APPROVED BY
ON BEHALF

APPROVED BY
ON BEHALF

